A Imitrex, Imigran ,Treximet CEP of the European Pharmacopoeia monograph is often referred to as a Imitrex, Imigran ,Treximet Certificate of Suitability (COS). The purpose of a Imitrex, Imigran ,Treximet CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Imitrex, Imigran ,Treximet EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Imitrex, Imigran ,Treximet to their clients by showing that a Imitrex, Imigran ,Treximet CEP has been issued for it. The manufacturer submits a Imitrex, Imigran ,Treximet CEP (COS) as part of the market authorization procedure, and it takes on the role of a Imitrex, Imigran ,Treximet CEP holder for the record. Additionally, the data presented in the Imitrex, Imigran ,Treximet CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Imitrex, Imigran ,Treximet DMF.
A Imitrex, Imigran ,Treximet CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Imitrex, Imigran ,Treximet CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Imitrex, Imigran ,Treximet suppliers with CEP (COS) on PharmaCompass.